Nanovic, Zorica
Preferred name
Nanovic, Zorica
Official Name
Nanovic, Zorica
Alternative Name
Zorica Risto Nanovikj
Zorica Nanovikj
Zorica R. Nanovic
Zorica R. Nanovikj
Zorica Risto Nanovic
Main Affiliation
Scopus Author ID
Scopus Author ID: 56015425000
9 results
Now showing 1 - 9 of 9
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study(European Respiratory Society (ERS), 2018) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Association of Inflammatory Markers with Disease Severity and Outcome in Covid-19 Patients(Macedonian Academy of Sciences and Arts, 2023-03-01); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Socio-demographic and clinical characteristics of patients with tuberculosis and diabetes in European countries. A TB-net study(European Respiratory Society, 2016-09) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, National advisory services for multidrug-resistant tuberculosis (MDRTB) in Europe: an ERS-TBnet survey(European Respiratory Society, 2019-09-28) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Burden and Characteristics of the Comorbidity Tuberculosis-Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study(Oxford University Press (OUP), 2019-01) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Key Issues in the Management of Multi-Drug Resistant Tuberculosis: A Case Report(ID-Design/Scientific foundation SPIROSKI, 2018-07-20); ; ; Global tuberculosis (TB) epidemic is being driven to an increasing extent by the emergence and spread of drug-resistant strains of Mycobacterium tuberculosis complex (MTBC). We present a case of primary multidrug-resistant tuberculosis (MDR-TB), highlighting Macedonian MDR-TB management issues. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, ANTISYNTHETASE SYNDROME: A RARE AND CHALLENGING DIAGNOSIS – CASE REPORT AND LITERATURE REVIEW(Central Medical Library - Bulgaria, 2022-10); ; ; Antisynthetase syndrome (ASS) is rare idiopathic inflammatory myopathy (IIM) characterized principally by myositis, generally symmetrical arthritis and interstitial lung disease (ILD) in association with serum autoantibodies to aminoacyl-transfer RNA synthetases. More variable features include arthralgia, Raynaud phenomenon, heliotrophic rash, distal esophageal dysmotility and mechanic's hands. In this case report we describe a 46-years old woman who initially presented with arthritis and subtle myositis which delayed the recognition of ASS and contributed for considering the condition as seronegative rheumatoid arthritis for several years. During the next few years, the patient was progressively worsening, with a disability to stand up from a sitting position, gradual onset of exertional dyspnea, difficult-to-control dry cough and thick, hyperkeratotic skin of both hands (mechanic’s hands). This constellation of symptoms was highly suspicious for ASS and additional serological and radiological examinations were done which confirmed the diagnosis. The need for further detailed investigation when an interstitial lung disease overlaps with a known rheumatoid condition is obligatory, as shown in this case. A multidisciplinary evaluation is highly recommended to evaluate the clinical, serological and radiological findings in each patient suspected for ASS in order to establish early diagnosis and timely management. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Legionnaires’ Disease and Use of Tumor Necrosis Factor-Αlpha Inhibitors: A Forthcoming Problem?(Scientific Foundation SPIROSKI, 2013-12-15); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Scrofuloderma- a rare but serious diagnostic challenge(Македонско лекарско друштво = Macedonian medical association/De Gruyter, 2024-04);